Dextrose Injections Outperform Hyaluronic Acid for Knee Osteoarthritis Pain

Osteoarthritis affects over 600 million people globally and is projected to exceed 1.1 billion cases by 2050, yet current treatments — NSAIDs, corticosteroids, and hyaluronic acid injections — address symptoms without modifying disease progression. This 2025 mini-review in Frontiers in Endocrinology by Huang and Cai synthesizes the growing body of clinical and mechanistic evidence for hypertonic dextrose prolotherapy (DPT) as a regenerative alternative, drawing on RCTs, meta-analyses, and network meta-analyses involving thousands of knee OA patients.

Biologically, DPT works by injecting 12.5–25% dextrose solutions into or around the affected joint, inducing a localized, controlled inflammatory response. This recruits key growth factors — transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF) — which drive fibroblast activation, collagen fiber deposition, chondrocyte anabolism, and proteoglycan synthesis. The net effect is extracellular matrix remodeling and tissue regeneration rather than mere symptom suppression.

A pivotal meta-analysis of 14 RCTs (n=978 patients) found that DPT significantly reduced pain and improved physical function and quality of life versus placebo. Critically, outcomes were dose- and time-dependent: more injections and longer follow-up correlated with better results. Combined intra-articular plus extra-articular injections outperformed intra-articular injections alone. Dropout rates were lower in DPT groups, and no significant increase in adverse events was observed. A concentration-comparison RCT found that 20% DPT produced the greatest improvements in VAS and WOMAC scores and knee flexion versus 5% and 10% concentrations, though all outperformed exercise-only controls.

Head-to-head comparisons reveal a nuanced picture. Against normal saline, DPT produced superior WOMAC pain, function, and composite scores plus EuroQol-5D improvements sustained at 52 weeks. Against hyaluronic acid, results were mixed: one study showed DPT significantly reduced urinary CTX-II (a cartilage degradation biomarker) and outperformed HA on pain and function, while another found HA superior for symptom relief. A large network meta-analysis of 80 RCTs (n>6,900) found DPT combined with physical therapy (PT) achieved the highest pain reduction (SMD = -2.54) and global function restoration (SMD = 2.28) of any regimen tested, surpassing PRP+PT, HA+DPT, and monotherapies. Against standalone PRP, DPT was slightly inferior in a small early-stage KOA trial, but superior when combined with PT in broader populations.

The review also highlights injection site as a meaningful variable. A three-arm RCT comparing intra-articular, peri-articular perineural, and combined injections found the combination produced the lowest VAS and WOMAC scores at 4 and 8 weeks, with higher pressure pain threshold values suggesting superior nerve sensitization relief. These findings suggest that multimodal DPT protocols targeting both intra- and peri-articular structures may maximize therapeutic benefit.

Despite promising results, the authors emphasize significant caveats. Heterogeneity in dextrose concentrations (5–25%), injection frequencies, target sites, and follow-up durations makes cross-study comparisons difficult. Most trials are short-term, and few include structural imaging endpoints to confirm cartilage preservation. Risk of bias remains a concern across included studies. The authors call for large, well-powered RCTs with standardized protocols, long-term follow-up, and biomarker endpoints to definitively establish DPT's role in OA management.